P779: CD patients in deep remission harbor a high dysbiosis index similar to active CD at diagnosis, yet both are higher in comparison to healthy controlsECCO '17 Barcelona
2017
P780: 3-oxo-C12:2-HSL, a new N-acyl-homoserine lactone identified in gut ecosystem exerts an anti-inflammatory effect and does not modify paracellular permeabilityECCO '17 Barcelona
2017
P781: The stability of the fecal microbiota in Crohn's disease patients with changing disease courseECCO '17 Barcelona
2017
P782: A new compatibility test for donor selection for faecal microbiota transplantation in ulcerative colitisECCO '17 Barcelona
2017
P783: Ciprofloxacin resistance in ESBL producing enterobacteriaceae colonizing the gut in IBD patientsECCO '17 Barcelona
2017
P784: A comparison study of the mucosa-associated microbiota between inflamed and non-inflamed sites in ulcerative colitis patientsECCO '17 Barcelona
2017
P785: Association of Bacteroidetes with endoscopic activity in patients with inflammatory bowel diseaseECCO '17 Barcelona
2017
P786: Correlation between the presence of Bacteroidetes and faecal calprotectin for the detection of endoscopic activity in patients with inflammatory bowel diseaseECCO '17 Barcelona
2017
P788: Microbiota related disease activity and distribution in subgroups of inflammatory bowel diseaseECCO '17 Barcelona
2017
P789: Microbiome composition is altered in patients with IBD independent of endoscopic activityECCO '17 Barcelona
2017
P790: Microbiota profile in pediatric IBD: correlations with phenotype and disease activityECCO '17 Barcelona
2017
P791: Activation of the aryl hydrocarbon receptor after simvastatin and recombinant antagonist of receptors of interleukin-1 treatment in a rat model of inflammatory bowel diseaseECCO '17 Barcelona
2017
P793: Microbial composition in IBD may influence clinical symptoms independent of endoscopic activityECCO '17 Barcelona
2017
DOP001: Genetic and environmental risk model to predict intestinal inflammation in asymptomatic first-degree relatives of Crohn’s disease patientsECCO '16 Amsterdam
2016
DOP002: Molecular response to ustekinumab in moderate-to-severe Crohn’s disease by serum protein analysis: results from the UNITI-1 and UNITI-2 Phase 3 induction studiesECCO '16 Amsterdam
2016